长期 AML 幸存者的克隆性血液形成:风险因素和临床后果
Simon M Krauß1, Eva Telzerow2, Daniel Richter3
1Department of Hematology, Cell Therapy, Hemostaseology and Infectiology University of Leipzig Medical Center Leipzig Germany.
HemaSphere
|July 25, 2025
概括
克隆性血液形成 (CH) 在急性髓性白血病 (AML) 幸存者中很常见,特别是那些接受化疗的人. 这种情况与糖尿病和二次癌症的风险增加有关.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 克隆性血液形成 (CH) 在一般人群中很普遍,与健康风险有关.
- 它的发生和急性髓性白血病 (AML) 长期幸存者 (LTS) 的影响尚不清楚.
研究的目的:
- 确定CH在AML LTS中的流行率和临床意义.
- 根据治疗方式,调查影响AMLLLTS中CH的因素.
主要方法:
- 在373个AML LTS中分析CH,随访时间中位数为11.6年.
- 利用使用单分子分子逆转探针的敏感向测序试验.
- 根据变异性等位基频率 (VAF) 分类的CH:小克隆CH (<2%VAF) 和不确定潜力的CH (≥2%VAF).
主要成果:
- 在61.9%的AML LTS中检测到CH.
- 仅接受化疗治疗的幸存者 (75.7%) 的CH患病率高于全源干细胞移植 (alloSCT) 接受者 (54.0%) 和对照组.
- 在接受化疗的幸存者中,CH的患病率与年龄相关,在alloSCT接受者中,血液生成年龄相关.
- 在接受化疗的幸存者中,特定变异 (TP53,PPM1D) 更常见.
- 冠状动脉变体 (≥10%VAF) 与alloSCT接受者糖尿病风险增加和化学疗法治疗幸存者的二次瘤有关.
结论:
- 在AML LTS中,CH的发病率很高.
- 治疗方式显著影响CH的患病率和相关风险.
- 在AML LTS中CH值得进一步研究其临床相关性和管理.
相关概念视频
01:22Bone Marrow Sampling and Transplants
502
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
502
01:21Lineage Commitment
3.1K
Commitment is the process whereby stem cells:
3.1K
01:19Multipotency of Hematopoietic Stem Cells
3.3K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.3K
01:01Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
01:21Stem Cell Therapy for Tissue Regeneration
4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
01:21Hematopoiesis
5.7K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.7K